Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- Written by PR Newswire Asia - News Pronto RSS
- Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC
- Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) for the treatment of ES-SCLC
- Serplulimab has now been approved in China, Europe, and several Southeast Asian countries, benefiting over 90,000 patients
SHA...